Focused On-demand Library for Tubulin alpha-8 chain

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Alpha-tubulin 8; Tubulin alpha chain-like 2

Alternative UPACC:

Q9NY65; B2RCX2; B3KPW9; B4DWG3; Q2M3N4


Tubulin alpha-8 chain, also known as Alpha-tubulin 8 and Tubulin alpha chain-like 2, plays a pivotal role in cell structure and function as the major constituent of microtubules. These microtubules are essential for various cellular processes, including cell division, intracellular transport, and maintenance of cell shape. The dynamic assembly of tubulin into microtubules involves the addition of GTP-tubulin dimers, facilitated by the GTPase activity of alpha-tubulin.

Therapeutic significance:

The Tubulin alpha-8 chain's involvement in Macrothrombocytopenia, an autosomal dominant blood disorder, highlights its potential as a target for therapeutic intervention. Understanding the role of Tubulin alpha-8 chain could open doors to potential therapeutic strategies, offering hope for individuals affected by this and possibly other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.